Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bloodstream Infections in a COVID-19 Non-ICU Department: Microbial Epidemiology, Resistance Profiles and Comparative Analysis of Risk Factors and Patients' Outcome.
Giannitsioti E, Louka C, Mamali V, Kousouli E, Velentza L, Papadouli V, Loizos G, Mavroudis P, Kranidiotis G, Rekleiti N, Stamati A, Speggos I, Daniil I, Kouvatsos P, Sidiropoulou C, Linardaki G, Gerakari S, Chrysos G, Themeli-Digalaki K, Zarkotou O. Giannitsioti E, et al. Microorganisms. 2022 Jun 29;10(7):1314. doi: 10.3390/microorganisms10071314. Microorganisms. 2022. PMID: 35889033 Free PMC article.
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis.
Kyriazopoulou E, Huet T, Cavalli G, Gori A, Kyprianou M, Pickkers P, Eugen-Olsen J, Clerici M, Veas F, Chatellier G, Kaplanski G, Netea MG, Pontali E, Gattorno M, Cauchois R, Kooistra E, Kox M, Bandera A, Beaussier H, Mangioni D, Dagna L, van der Meer JWM, Giamarellos-Bourboulis EJ, Hayem G; International Collaborative Group for Anakinra in COVID-19. Kyriazopoulou E, et al. Lancet Rheumatol. 2021 Oct;3(10):e690-e697. doi: 10.1016/S2665-9913(21)00216-2. Epub 2021 Aug 9. Lancet Rheumatol. 2021. PMID: 34396156 Free PMC article.
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, Fragkou A, Rapti A, Damoulari C, Fantoni M, Kalomenidis I, Chrysos G, Angheben A, Kainis I, Alexiou Z, Castelli F, Serino FS, Tsilika M, Bakakos P, Nicastri E, Tzavara V, Kostis E, Dagna L, Koufargyris P, Dimakou K, Savvanis S, Tzatzagou G, Chini M, Cavalli G, Bassetti M, Katrini K, Kotsis V, Tsoukalas G, Selmi C, Bliziotis I, Samarkos M, Doumas M, Ktena S, Masgala A, Papanikolaou I, Kosmidou M, Myrodia DM, Argyraki A, Cardellino CS, Koliakou K, Katsigianni EI, Rapti V, Giannitsioti E, Cingolani A, Micha S, Akinosoglou K, Liatsis-Douvitsas O, Symbardi S, Gatselis N, Mouktaroudi M, Ippolito G, Florou E, Kotsaki A, Netea MG, Eugen-Olsen J, Kyprianou M, Panagopoulos P, Dalekos GN, Giamarellos-Bourboulis EJ. Kyriazopoulou E, et al. Among authors: giannitsioti e. Nat Med. 2021 Oct;27(10):1752-1760. doi: 10.1038/s41591-021-01499-z. Epub 2021 Sep 3. Nat Med. 2021. PMID: 34480127 Free PMC article. Clinical Trial.
Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, Fragkou A, Rapti A, Damoulari C, Fantoni M, Kalomenidis I, Chrysos G, Angheben A, Kainis I, Alexiou Z, Castelli F, Serino FS, Tsilika M, Bakakos P, Nicastri E, Tzavara V, Kostis E, Dagna L, Koufargyris P, Dimakou K, Savvanis S, Tzatzagou G, Chini M, Cavalli G, Bassetti M, Katrini K, Kotsis V, Tsoukalas G, Selmi C, Bliziotis I, Samarkos M, Doumas M, Ktena S, Masgala A, Papanikolaou I, Kosmidou M, Myrodia DM, Argyraki A, Cardellino CS, Koliakou K, Katsigianni EI, Rapti V, Giannitsioti E, Cingolani A, Micha S, Akinosoglou K, Liatsis-Douvitsas O, Symbardi S, Gatselis N, Mouktaroudi M, Ippolito G, Florou E, Kotsaki A, Netea MG, Eugen-Olsen J, Kyprianou M, Panagopoulos P, Dalekos GN, Giamarellos-Bourboulis EJ. Kyriazopoulou E, et al. Among authors: giannitsioti e. Nat Med. 2021 Oct;27(10):1850. doi: 10.1038/s41591-021-01569-2. Nat Med. 2021. PMID: 34625750 Free PMC article. No abstract available.
Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic joint infections: Role of surgery and impact of colistin administration.
Papadopoulos A, Ribera A, Mavrogenis AF, Rodriguez-Pardo D, Bonnet E, Salles MJ, Dolores Del Toro M, Nguyen S, Blanco-García A, Skaliczki G, Soriano A, Benito N, Petersdorf S, Pasticci MB, Tattevin P, Tufan ZK, Chan M, O'Connell N, Pantazis N, Kyprianou A, Pigrau C, Megaloikonomos PD, Senneville E, Ariza J, Papagelopoulos PJ, Giannitsioti E; ESCMID Study Group for Implant-Associated Infections (ESGIAI). Papadopoulos A, et al. Among authors: giannitsioti e. Int J Antimicrob Agents. 2019 Mar;53(3):294-301. doi: 10.1016/j.ijantimicag.2018.10.018. Epub 2018 Nov 3. Int J Antimicrob Agents. 2019. PMID: 30395988
Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure.
Giamarellos-Bourboulis EJ, Poulakou G, de Nooijer A, Milionis H, Metallidis S, Ploumidis M, Grigoropoulou P, Rapti A, Segala FV, Balis E, Giannitsioti E, Rodari P, Kainis I, Alexiou Z, Focà E, Lucio B, Rovina N, Scorzolini L, Dafni M, Ioannou S, Tomelleri A, Dimakou K, Tzatzagou G, Chini M, Bassetti M, Trakatelli C, Tsoukalas G, Selmi C, Samaras C, Saridaki M, Pyrpasopoulou A, Kaldara E, Papanikolaou I, Argyraki A, Akinosoglou K, Koupetori M, Panagopoulos P, Dalekos GN, Netea MG. Giamarellos-Bourboulis EJ, et al. Among authors: giannitsioti e. Cell Rep Med. 2022 Feb 25;3(3):100560. doi: 10.1016/j.xcrm.2022.100560. eCollection 2022 Mar 15. Cell Rep Med. 2022. PMID: 35474750 Free PMC article.
Osteosynthesis-associated infection of the lower limbs by multidrug-resistant and extensively drug-resistant Gram-negative bacteria: a multicentre cohort study.
Giannitsioti E, Salles MJ, Mavrogenis A, Rodriguez-Pardo D, Los-Arcos I, Ribera A, Ariza J, Del Toro MD, Nguyen S, Senneville E, Bonnet E, Chan M, Pasticci MB, Petersdorf S, Benito N, O' Connell N, Blanco García A, Skaliczki G, Tattevin P, Kocak Tufan Z, Pantazis N, Megaloikonomos PD, Papagelopoulos P, Soriano A, Papadopoulos A, The Esgiai Collaborators Study Group. Giannitsioti E, et al. J Bone Jt Infect. 2022 Dec 21;7(6):279-288. doi: 10.5194/jbji-7-279-2022. eCollection 2022. J Bone Jt Infect. 2022. PMID: 36644590 Free PMC article.
Pan-Echinocandin Resistant C. parapsilosis Harboring an F652S Fks1 Alteration in a Patient with Prolonged Echinocandin Therapy.
Siopi M, Papadopoulos A, Spiliopoulou A, Paliogianni F, Abou-Chakra N, Arendrup MC, Damoulari C, Tsioulos G, Giannitsioti E, Frantzeskaki F, Tsangaris I, Pournaras S, Meletiadis J. Siopi M, et al. Among authors: giannitsioti e. J Fungi (Basel). 2022 Sep 1;8(9):931. doi: 10.3390/jof8090931. J Fungi (Basel). 2022. PMID: 36135656 Free PMC article.
81 results